Skip to main content
OpenTrials
Completed

NCT Number: NCT01666067

Vascular and Metabolic Effects of Vytorin vs Simvastatin

The investigators hypothesize that vytorin will improve insulin resistance compared with simvastatin

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Dyslipidemias Glucose Metabolism Disorders Hyperinsulinism Hyperlipidemias Insulin Resistance Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

25 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Gil Medical Center

Incheon, 405-760, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hypercholesterolemic patients (LDL cholesterol levels>100 mg/dl)

Exclusion criteria

  • overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c > 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Treatment and study plan

Placebo

Drug

vytorin

Drug

simvastatin

Drug

Primary outcomes

  1. flow-mediated dilation

    Time frame: 8 weeks of treatment

Secondary outcomes

  1. insulin resistance

    Time frame: 8 weeks of treatment

Sponsors and collaborators

Lead sponsor

Gachon University Gil Medical Center

Other

Registry information

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Aug 16, 2012
Registry last updated
Nov 4, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.